Longeveron (LGVN) announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy. The accepted IND application provides for moving directly to a single Phase 2 pivotal registration clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron appoints Powell as Chief Business Officer
- Positive Buy Rating for Longeveron Driven by Phase 2b Study Milestone and Favorable Market Conditions
- Longeveron completes enrollment of Phase 2b trial of laromestrocel in HLHS
- Longeveron Elects New Director at Annual Meeting
- Longeveron management to meet with Roth MKM